文献速递头颈部肿瘤放疗

HPV阳性口咽癌治疗降强度:2019年研究回顾

De-intensification for HPV positive oropharyngeal cancer: and yet it moves!: 2019 in review.
PubMed 文献 · Clin Transl Radiat Oncol · 2020-03-07

本文为迷你综述,聚焦2019年发表的三项关于HPV阳性口咽癌治疗降强度的新试验。文章指出HPV感染对口咽鳞癌预后有强阳性影响,患者通常较年轻且合并症少,死于原发病、第二原发肿瘤或间期死亡的风险较低。综述讨论了在降低标准同步放化疗毒性的同时不损害疗效的降强度策略及其对临床实践的潜在意义。

要点

  • HPV阳性口咽癌患者预后显著优于HPV阴性者,通常较年轻且合并症负担低。
  • 降强度策略旨在减少标准同步放化疗所致毒性而不损害疗效。
  • 2019年发表的三项新试验为HPV阳性口咽癌降强度治疗提供了新证据。

核心结论

  • HPV阳性口咽癌因预后显著优于HPV阴性者,具备开展治疗降强度的合理基础。
  • 2019年发表的三项新试验为降强度策略的临床转化提供了重要参考。

研究设计与样本

  • 本文为迷你综述,聚焦2019年发表的三项前瞻性降强度试验。

主要发现

  • HPV阳性口咽癌患者通常处于壮年且合并症负担低,死于原发病、第二原发肿瘤或间期死亡的风险较低。
  • 全球已开展多项前瞻性研究,共同目标是探索降强度框架下的替代治疗范式。

临床怎么用

  • 临床可参考2019年三项新试验的结果,评估HPV阳性口咽癌降强度治疗的适用性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the last decade, the recognition of the strongly positive prognostic impact of human papilloma virus (HPV) infection on the natural history of squamous cell carcinoma of the oropharynx has reshaped the historical monolithic view of a "one-size-fits-all approach" for head and neck cancer. Unlike their HPV negative counterparts, patients affected by HPV positive oropharyngeal cancer are usually in their prime with a low burden of comorbidities: most importantly, they are less likely to die for their disease, for second primary tumors or for intercurrent mortality. On these grounds, the scientific community was confronted with a pragmatic question: can the morbidity induced by standard concurrent chemo-radiotherapy be reduced without compromising efficacy? Worldwide, several prospective studies were launched, with the common aim to look for alternative treatment paradigms in the frame of de-intensification. This mini-review focuses on three new important trials published in 2019 and discusses their potential implications for clinical practice in the management of patients with HPV positive oropharyngeal cancer.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Bonomo P, Livi L. De-intensification for HPV positive oropharyngeal cancer: and yet it moves!: 2019 in review. Clin Transl Radiat Oncol. 2020. PMID: 32195379. doi:10.1016/j.ctro.2020.03.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。